April 2025 | Volume 24 | Issue 4 | 413 | Copyright April 2025 Published online March 7, 2025 doi:10.36849/JDD.8605 Sophia Daniel BS a,b , Stephanie Waggett BS a,c , Elliott Lyles BS a , Pelin Sagut MD a,d , Parisa Shamaei Zadeh MSPH b , Anthony Marcelletti BHS b , Carol Stegura ME c , Lara Wine Lee MD PhD d a College of Graduate Studies, Medical University of South Carolina, Charleston, SC b College of Medicine, University of Kentucky, Lexington, KY c College of Medicine, Medical University of South Carolina, Charleston, SC d Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, SC Abstract Glucagon-like peptide-1 (GLP-1) agonists are used to treat type 2 diabetes mellitus (T2DM) and have recently gained approval and popularity for treating obesity and weight loss
While it raises growth hormone levels, it cannot reopen growth plates or make bones grow longer once they have fused
Long-Lasting Effects : With regular sessions, you can maintain your skins health and youthful appearance
This review summarises the clinical evidence for GLP-1RAs and how they compare to other glucose-lowering agents in managing type 2 diabetes